Condition
Acute Myeloid Leukemias
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 3 (1)
Trial Status
Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07211958Phase 3RecruitingPrimary
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT06226571Phase 1RecruitingPrimary
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06950034Phase 1Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT01220544Phase 1UnknownPrimary
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Showing all 4 trials